MacroGenics (MGNX) Corporate presentation summary

Platform technologies and pipeline

• Proprietary DART and TRIDENT platforms enable development of next-generation antibody-based therapeutics for cancer, including ADCs, dual checkpoint inhibitors, and T-cell engagers.

• Four clinical-stage candidates and three FDA-approved products, with significant rights retained for pipeline assets.

• Broad clinical pipeline includes MGC026, MGC028, MGC030 (all ADCs), lorigerlimab (dual checkpoint), and MGD024 (T-cell engager).

ADC portfolio and differentiation

• ADCs utilize Synaffix's proprietary linker-toxin technology, offering higher potency and less sensitivity to drug resistance mechanisms.

• MGC026 targets B7-H3, showing superior preclinical anti-tumor activity and higher internalization rates compared to competitors.

• MGC028 targets ADAM9, overexpressed in multiple cancers, with promising safety and efficacy in preclinical and early clinical studies.

• MGC030 targets an undisclosed antigen, with IND submission planned for 3Q2026.

Clinical development and milestones

• MGC026 and MGC028 are in Phase 1 dose expansion and escalation, with initial data expected in mid and late 2026, respectively.

• Lorigerlimab, a PD-1 × CTLA-4 DART molecule, is in Phase 2 for ovarian and gynecologic cancers; study is on partial clinical hold pending FDA resolution.

• MGD024, a next-generation CD123 × CD3 DART, is in Phase 1 for hematologic malignancies, with favorable preclinical and early clinical data.